Your browser doesn't support javascript.
loading
Cost Burden of Endothelial Keratoplasty in Fuchs Endothelial Dystrophy: Real-World Analysis of a Commercially Insured US Population (2014-2019).
Dhaliwal, Deepinder K; Chirikov, Viktor; Schmier, Jordana; Rege, Sanika; Newton, Schalon.
Afiliación
  • Dhaliwal DK; Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Chirikov V; OPEN Health Evidence & Access, Bethesda, MD, USA.
  • Schmier J; OPEN Health Evidence & Access, Bethesda, MD, USA.
  • Rege S; OPEN Health Evidence & Access, Bethesda, MD, USA.
  • Newton S; Trefoil Therapeutics, Inc., San Diego, CA, USA.
Clin Ophthalmol ; 16: 1055-1067, 2022.
Article en En | MEDLINE | ID: mdl-35418743
ABSTRACT

Purpose:

To assess the incremental burden of corneal transplant surgery for US commercially insured patients with Fuchs endothelial corneal dystrophy (FECD) treated with endothelial keratoplasty (EK) compared to controls.

Methods:

The study design was retrospective cohort using IBM® MarketScan® claims (January 2014-September 2019) and included EK-treated (N=1562) and control patients (N=23,485) having ≥12 months' enrollment before and after diagnosis, who were subsequently matched on select characteristics. The index date was the beginning of the pre-operative period (3 months before EK); synthetic EK index was assigned for controls. All-cause, eye-disease, and complication-related healthcare resource utilization (HCRU) and costs were compared up to 36 months post index. For a small subset of patients, patient data were linked to the Health and Productivity Management supplemental database, which integrates data on productivity loss and disability payments.

Results:

Matched cohorts included 804 EK-treated and 1453 controls with average age 65.7 years, 1383 (61%) female. Over 12 months of follow-up, all-cause ($41,199 vs $20,222, p<0.001) and eye-disease related costs ($22,951 vs $1389, p<0.001) were higher among EK-treated patients than controls. The cost differential increased additionally by $1000-$2000 per annum by 36 months of follow-up. While balanced at baseline, over follow-up EK-treated patients had higher prevalence of glaucoma, elevated intraocular pressure, cataract, cataract surgery, diagnosis of cornea transplant rejection, retinal edema. By 36 month of follow-up, EK-treated patients had 9 more short-term disability days, resulting in $2992 additional burden of disability payments.

Conclusion:

This study found a higher cost burden among FECD patients receiving EK treatment versus those who did not. With a shift in management of FECD, cost burden estimates generated in this study could serve as an important benchmark for future studies.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Health_economic_evaluation / Risk_factors_studies Idioma: En Revista: Clin Ophthalmol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Health_economic_evaluation / Risk_factors_studies Idioma: En Revista: Clin Ophthalmol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos